Investing in biotechnology is known to be tough, as startups often face years of development time, clinical trials and regulatory work before maturing to the point where they can offer returns for the investors. But Kleiner Perkins Caufield & Byers recently bucked that trend, reaping well over 10 times what it put into immunotherapy company Flexus Biosciences Inc. in less than a year and a half.